These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 36293371)

  • 1. Mulberry Component Kuwanon C Exerts Potent Therapeutic Efficacy In Vitro against COVID-19 by Blocking the SARS-CoV-2 Spike S1 RBD:ACE2 Receptor Interaction.
    Kim YS; Kwon EB; Kim B; Chung HS; Choi G; Kim YH; Choi JG
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mulberrofuran G, a Mulberry Component, Prevents SARS-CoV-2 Infection by Blocking the Interaction between SARS-CoV-2 Spike Protein S1 Receptor-Binding Domain and Human Angiotensin-Converting Enzyme 2 Receptor.
    Kim YS; Kim B; Kwon EB; Chung HS; Choi JG
    Nutrients; 2022 Oct; 14(19):. PubMed ID: 36235822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
    Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
    mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
    Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
    J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
    David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
    Molecules; 2021 May; 26(11):. PubMed ID: 34072087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2.
    Prajapat M; Shekhar N; Sarma P; Avti P; Singh S; Kaur H; Bhattacharyya A; Kumar S; Sharma S; Prakash A; Medhi B
    J Mol Graph Model; 2020 Dec; 101():107716. PubMed ID: 32866780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kobophenol A Inhibits Binding of Host ACE2 Receptor with Spike RBD Domain of SARS-CoV-2, a Lead Compound for Blocking COVID-19.
    Gangadevi S; Badavath VN; Thakur A; Yin N; De Jonghe S; Acevedo O; Jochmans D; Leyssen P; Wang K; Neyts J; Yujie T; Blum G
    J Phys Chem Lett; 2021 Feb; 12(7):1793-1802. PubMed ID: 33577324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding.
    Yang LJ; Chen RH; Hamdoun S; Coghi P; Ng JPL; Zhang DW; Guo X; Xia C; Law BYK; Wong VKW
    Phytomedicine; 2021 Jul; 87():153591. PubMed ID: 34029937
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Tiwari V
    Biol Open; 2020 Oct; 9(10):. PubMed ID: 32878881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of Pseudotyped Coronaviruses for the Screening of Entry Inhibitors: Green Tea Extract Inhibits the Entry of SARS-CoV-1, MERSCoV, and SARS-CoV-2 by Blocking Receptor-spike Interaction.
    Joseph J; Karthika T; Das VRA; Raj VS
    Curr Pharm Biotechnol; 2022; 23(8):1118-1129. PubMed ID: 34375189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Common cardiac medications potently inhibit ACE2 binding to the SARS-CoV-2 Spike, and block virus penetration and infectivity in human lung cells.
    Caohuy H; Eidelman O; Chen T; Liu S; Yang Q; Bera A; Walton NI; Wang TT; Pollard HB
    Sci Rep; 2021 Nov; 11(1):22195. PubMed ID: 34773067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACE2-derived peptides interact with the RBD domain of SARS-CoV-2 spike glycoprotein, disrupting the interaction with the human ACE2 receptor.
    Souza PFN; Amaral JL; Bezerra LP; Lopes FES; Freire VN; Oliveira JTA; Freitas CDT
    J Biomol Struct Dyn; 2022 Aug; 40(12):5493-5506. PubMed ID: 33427102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of natural compounds as SARS-CoV-2 entry inhibitors by molecular docking-based virtual screening with bio-layer interferometry.
    Zhang D; Hamdoun S; Chen R; Yang L; Ip CK; Qu Y; Li R; Jiang H; Yang Z; Chung SK; Liu L; Wong VKW
    Pharmacol Res; 2021 Oct; 172():105820. PubMed ID: 34403732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2.
    Larue RC; Xing E; Kenney AD; Zhang Y; Tuazon JA; Li J; Yount JS; Li PK; Sharma A
    Bioconjug Chem; 2021 Jan; 32(1):215-223. PubMed ID: 33356169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
    Qiao B; Olvera de la Cruz M
    ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 spike protein and its host cell receptor ACE2.
    Li C; Zhou H; Guo L; Xie D; He H; Zhang H; Liu Y; Peng L; Zheng L; Lu W; Mei Y; Liu Z; Huang J; Wang M; Shu D; Ding L; Lang Y; Luo F; Wang J; Huang B; Huang P; Gao S; Chen J; Qian CN
    J Transl Med; 2022 Jul; 20(1):314. PubMed ID: 35836239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces.
    Lapaillerie D; Charlier C; Guyonnet-Dupérat V; Murigneux E; Fernandes HS; Martins FG; Magalhães RP; Vieira TF; Richetta C; Subra F; Lebourgeois S; Charpentier C; Descamps D; Visseaux B; Weigel P; Favereaux A; Beauvineau C; Buron F; Teulade-Fichou MP; Routier S; Gallois-Montbrun S; Meertens L; Delelis O; Sousa SF; Parissi V
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0008322. PubMed ID: 35861550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.